- Home
- GLP vs GERN Comparison
GLP vs GERN Comparison
Compare GLP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLP
- GERN
- Stock Information
- Founded
- GLP 2005
- GERN 1990
- Country
- GLP United States
- GERN United States
- Employees
- GLP N/A
- GERN N/A
- Industry
- GLP Oil Refining/Marketing
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- GLP Energy
- GERN Health Care
- Exchange
- GLP Nasdaq
- GERN Nasdaq
- Market Cap
- GLP N/A
- GERN 1.5B
- IPO Year
- GLP 2005
- GERN 1996
- Fundamental
- Price
- GLP $54.21
- GERN $1.65
- Analyst Decision
- GLP Hold
- GERN Buy
- Analyst Count
- GLP 1
- GERN 11
- Target Price
- GLP $56.00
- GERN $5.80
- AVG Volume (30 Days)
- GLP 70.8K
- GERN 14.9M
- Earning Date
- GLP 05-07-2025
- GERN 05-01-2025
- Dividend Yield
- GLP 5.37%
- GERN N/A
- EPS Growth
- GLP N/A
- GERN N/A
- EPS
- GLP 2.41
- GERN N/A
- Revenue
- GLP $17,163,565,999.00
- GERN $76,994,000.00
- Revenue This Year
- GLP $44.97
- GERN $208.83
- Revenue Next Year
- GLP $8.73
- GERN $57.49
- P/E Ratio
- GLP $22.42
- GERN N/A
- Revenue Growth
- GLP 4.07
- GERN 32386.92
- 52 Week Low
- GLP $37.00
- GERN $1.46
- 52 Week High
- GLP $60.00
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- GLP 47.85
- GERN 34.01
- Support Level
- GLP $51.98
- GERN $1.63
- Resistance Level
- GLP $54.48
- GERN $1.89
- Average True Range (ATR)
- GLP 1.82
- GERN 0.11
- MACD
- GLP -0.07
- GERN 0.04
- Stochastic Oscillator
- GLP 50.45
- GERN 21.87
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.